Pharmacology: Imatinib is a small molecule protein-tyrosin kinase inhibitor that potently inhibits the activity of the BCR-ABL tyrosin kinase (TK), as well as several receptor TKs; KIT, the receptor for stem cell factor (SCF) coded for by the c-Kit proto-oncogene, the discoidin domain receptors (DDR1 and DDR2) the colony stimulating factor receptor (CSF-1R) and the platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta). Imatinib can also inhibit cellular events mediated by activation of these receptor kinases.
Sign Out
